CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 ...

Seres Therapeutics Inc. plans to start selling its first FDA-approved product, a drug called Vowst made of bacterial spores derived from donated feces, this summer at $17,500 a course.